Hormonal
Dual GLP-1/GIP receptor agonists (e.g., tirzepatide) produce significantly greater weight loss and glycemic control than selective GLP-1 receptor agonists by synergistically targeting both incretin pathways.
If you have T2DM or obesity, dual GLP-1/GIP agonists like tirzepatide are currently the most effective pharmacological option for weight loss and blood sugar control, outperforming older GLP-1 drugs. They are taken as a once-weekly injection. Discuss with your doctor if this advanced therapy is appropriate for your specific health profile.
Tirzepatide is the first dual glucose-dependent insulinotropic polypeptide (GIP)/GLP- 1 receptor co-agonist approved for the treatment of T2DM in the USA, Europe, and the United Arab Emirates [4]; it causes an average weight loss of an astounding 22% in individuals with obesity.
Why this rating
The paper cites multiple clinical trials and preclinical models showing consistent superiority, though it is a review rather than a single primary trial.
Source
Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data
Ioanna A. Anastasiou et al. · Current Obesity Reports · 2025
DOI 10.1007/s13679-025-00623-1
More from this paper
- Triple agonists targeting GLP-1, GIP, and Glucagon receptors improve energy expenditure and restore body weight in diet-induced obesity models more effectively than dual or mono-agonists.Moderate
- GIP receptor agonism contributes to insulin sensitivity independently of weight loss by promoting glucose capture in white adipose tissue and catabolism of branched-chain amino acids in brown adipose tissue.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →